|
WO2019175328A1
|
|
Bh4pathwayactivationandusethereoffortreatingcancer
|
|
WO2019175332A1
|
|
Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity
|
|
WO2019073055A1
|
|
Enhanced reprogramming of somatic cells
|
|
AU2018285579A1
|
|
Blood vessel organoid, methods of producing and using said organoids
|
|
EP3589748A1
|
|
Nucleic acid modification and identification method
|
|
AU2017277735A1
|
|
Cbl-family inhibitor comprising a Cbl-family TKB domain binding peptide for the prevention or treatment of diseases
|
|
EP3395942A1
|
|
Bi- or multi-differentiated organoid
|
|
EP3388530A1
|
|
Nucleic acid modification and identification method
|
|
EP3379249A1
|
|
Method of detecting polycomb repressive complex activity
|
|
US2019085325A1
|
|
Conditional crispr sgrna expression
|
|
CA2867085A1
|
|
Archease as rna ligase complex member
|
|
EP2702998A1
|
|
Therapeutic and diagnostic miRNA regulator in kidney disease
|
|
EP2599859A1
|
|
Haploid cells
|
|
WO2011117259A1
|
|
Methods for identifying inhibitors of the type iii secretion system
|
|
EP2434285A1
|
|
Breast cancer diagnostics
|
|
EP2433644A1
|
|
Breast cancer therapeutics
|
|
EP2423304A1
|
|
Use of a RNA ligase
|
|
EP2042592A1
|
|
Methods for modulating the proliferation and differentiation potential of stem cells and progenitor cells
|
|
EP1862538A1
|
|
siRNA kinase and methods of use
|
|
EP1854458A1
|
|
Use of a compound with RANKL activity
|
